Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA

Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA

Marco D DiBonaventura,1 William Wong,2 Bijal Shah-Manek,3,4 Mathias Schulz2 1Ipsos Healthcare, Global Evidence, Value & Access, New York, NY, 2Genentech, US Medical Affairs, San Francisco, CA, 3Ipsos Healthcare, Global Evidence, Value & Access, San Francisco, CA, 4College of Pharmac...

Full description

Bibliographic Details
Main Authors: DiBonaventura MD, Wong W, Shah-Manek B, Schulz M
Format: Article
Language:English
Published: Dove Medical Press 2017-12-01
Series:OncoTargets and Therapy
Subjects:
alectinib
anaplastic lymphoma kinase
non-small cell lung cancer
treatment patterns
outcomes
Online Access:https://www.dovepress.com/real-world-usage-and-clinical-outcomes-of-alectinib-among-post-crizoti-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/real-world-usage-and-clinical-outcomes-of-alectinib-among-post-crizoti-peer-reviewed-article-OTT

Similar Items